

Torben Bjerregaard Larsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6456250/publications.pdf>

Version: 2024-02-01

149
papers

6,541
citations

71102

41
h-index

66911

78
g-index

150
all docs

150
docs citations

150
times ranked

7601
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	1.7	951
2	Efficacy and Safety of Dabigatran Etxilate and Warfarin in "Real-World" Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2264-2273.	2.8	387
3	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2016, 353, i3189.	6.0	351
4	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.3	275
5	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 738-746.	2.8	272
6	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1030.	7.4	262
7	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. <i>Circulation</i> , 2015, 132, 517-525.	1.6	225
8	Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: A population-based nested case-control study. <i>Thrombosis Research</i> , 2007, 120, 505-509.	1.7	214
9	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA ₂ DS ₂ -VASc Score. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1385-1394.	2.8	141
10	Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort. <i>American Journal of Medicine</i> , 2014, 127, 295-302.	1.5	140
11	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. <i>BMJ, The</i> , 2012, 345, e7097-e7097.	6.0	110
12	Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 650-656.e5.	1.5	100
13	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 981-988.	3.4	99
14	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 640.e9-640.e17.	1.5	91
15	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 418-429.	3.3	87
16	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	1.8	83
17	Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 251-260.	3.8	82
18	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017, 177, 563.	5.1	75

#	ARTICLE	IF	CITATIONS
19	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2168-2174.	2.0	72
20	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	1.7	67
21	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016, 6, 27410.	3.3	67
22	Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. <i>Critical Care</i> , 2010, 14, R41.	5.8	64
23	Myocardial Ischemic Events in "Real World"™ Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. <i>American Journal of Medicine</i> , 2014, 127, 329-336.e4.	1.5	63
24	ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 300-304.	3.8	61
25	Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1236-1244.	1.9	60
26	Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2018, 131, 1067-1074.e4.	1.5	55
27	Preoperative Plasma D-Dimer Is a Predictor of Postoperative Deep Venous Thrombosis in Colorectal Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 446-451.	1.3	54
28	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>PLoS ONE</i> , 2014, 9, e114445.	2.5	54
29	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015, 101, 1446-1455.	2.9	54
30	Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 1896-1902.	1.7	53
31	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013, 99, 1093-1099.	2.9	51
32	Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1989-1997.	1.3	51
33	β ₂ -Blockers in Atrial Fibrillation Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002597.	3.9	49
34	The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. <i>PLoS ONE</i> , 2017, 12, e0188482.	2.5	48
35	Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 92-96.	0.3	46
36	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1596-1600.	1.7	46

#	ARTICLE	IF	CITATIONS
37	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018, 131, 574.e13-574.e27.	1.5	46
38	Hyperhomocysteinaemia, Coagulation Pathway Activation and Thrombophilia in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 62-67.	1.5	44
39	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. <i>JAMA Cardiology</i> , 2017, 2, 872.	6.1	44
40	Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A Nationwide, Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2283-2293.	5.8	44
41	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2014, 127, 1172-1178.e5.	1.5	43
42	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1651-1658.	0.8	43
43	The Arg506Gln Mutation (FV Leiden) Among a Cohort of 4188 Unselected Danish Newborns. <i>Thrombosis Research</i> , 1998, 89, 211-215.	1.7	41
44	A review of medical records and discharge summary data found moderate to high predictive values of discharge diagnoses of venous thromboembolism during pregnancy and postpartum. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 316-319.	5.0	41
45	International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. <i>Thrombosis and Haemostasis</i> , 2009, 101, 563-569.	3.4	41
46	Added Predictive Ability of the CHA ₂ DS ₂ -VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 335-342.	2.2	41
47	Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. <i>Epidemiology</i> , 2003, 14, 328-32.	2.7	41
48	Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2027-2031.	3.8	40
49	Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1301-1307.	3.8	39
50	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007030.	4.8	39
51	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>Clinical Research in Cardiology</i> , 2015, 104, 1088-1096.	3.3	36
52	Recurrent Stroke. <i>Stroke</i> , 2015, 46, 2491-2497.	2.0	36
53	Patients' knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2018, 20, 386-391.	1.7	35
54	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. <i>Chest</i> , 2014, 146, 1337-1346.	0.8	34

#	ARTICLE	IF	CITATIONS
55	Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2017, 19, 1737-1742.	1.7	34
56	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 939-946.	2.0	34
57	Validity of D-dimer tests in the diagnosis of deep vein thrombosis: a prospective comparative study of three quantitative assays. <i>Journal of Internal Medicine</i> , 2002, 252, 36-40.	6.0	32
58	Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 314-317.	1.7	30
59	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 857-873.	1.5	27
60	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating "valvular heart disease"™ in a nationwide cohort study. <i>Europace</i> , 2019, 21, 33-40.	1.7	27
61	Self-testing and self-management of oral anticoagulation therapy in children. <i>Thrombosis and Haemostasis</i> , 2011, 106, 391-397.	3.4	24
62	Warfarin or novel oral anticoagulants for atrial fibrillation?. <i>Lancet</i> , The, 2014, 383, 931-933.	13.7	23
63	Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. <i>BMJ Open</i> , 2017, 7, e018209.	1.9	23
64	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. <i>PLoS ONE</i> , 2014, 9, e113627.	2.5	22
65	Indirect comparison studies "are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 405-406.	3.4	21
66	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020, 125, 48-54.	1.6	20
67	Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 358-365.	1.0	18
68	Atrial Fibrillation Patients Categorized as "Not for Anticoagulation" According to the 2014 Canadian Cardiovascular Society Algorithm Are Not "Low Risk". <i>Canadian Journal of Cardiology</i> , 2015, 31, 24-28.	1.7	17
69	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 787-794.e4.	1.5	17
70	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, e269-e279.	1.5	17
71	Anticoagulant therapy after venous thromboembolism and 10-year mortality. <i>International Journal of Cardiology</i> , 2016, 208, 72-78.	1.7	16
72	Prevention of Venous Thromboembolism with New Oral Anticoagulants versus Standard Pharmacological Treatment in Acute Medically Ill Patients. <i>Drugs</i> , 2012, 72, 1755-1764.	10.9	15

#	ARTICLE	IF	CITATIONS
73	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. <i>Thrombosis Research</i> , 2015, 135, 643-647.	1.7	15
74	Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 209, 1-6.	1.7	15
75	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019, 108, 101-109.	3.3	15
76	Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 868-876.e5.	1.5	15
77	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 819-824.	1.7	14
78	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2018, 8, 15805.	3.3	14
79	Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. <i>Cancer Medicine</i> , 2019, 8, 1044-1053.	2.8	14
80	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f101-f110.	3.0	14
81	Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2017, 19, euw107.	1.7	13
82	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 805-814.	3.4	13
83	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, S45-S60.	3.4	12
84	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. <i>Circulation</i> , 2021, 143, 907-920.	1.6	12
85	Evaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral Anticoagulation. <i>Thrombosis Research</i> , 2000, 98, 157-163.	1.7	11
86	Rivaroxaban as anticoagulant therapy in short bowel syndrome. Report of three cases. <i>Thrombosis Research</i> , 2015, 135, 568-570.	1.7	11
87	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1494-1499.	1.3	11
88	Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 979-985.	2.0	11
89	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. <i>ESC Heart Failure</i> , 2018, 5, 319-326.	3.1	11
90	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2018, 72, e13258.	1.7	11

#	ARTICLE	IF	CITATIONS
91	Combined use of clinical pre-test probability and D-dimer test in the diagnosis of preoperative deep venous thrombosis in colorectal cancer patients. <i>Thrombosis and Haemostasis</i> , 2008, 99, 396-400.	3.4	10
92	Improvement of anticoagulant treatment using a dynamic decision support algorithm. <i>Thrombosis Research</i> , 2014, 133, 375-379.	1.7	9
93	Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 524-529.	3.4	9
94	Recalibration of the HAS-BLED Score. <i>Chest</i> , 2016, 149, 311-314.	0.8	9
95	Self-managed oral anticoagulant therapy: a call for implementation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 255-257.	1.5	9
96	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020, 191, 1-8.	1.7	9
97	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021, 10, 4405-4414.	2.8	8
98	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 698-702.	1.7	7
99	Clinical risk factors for retinal artery occlusions: a nationwide case-control study. <i>International Ophthalmology</i> , 2022, 42, 2483-2491.	1.4	7
100	Effect of Anticoagulant Therapy on the Hypercoagulable State in Patients Carrying the Factor V Arg506Gln Mutation. <i>Thrombosis Research</i> , 1998, 92, 157-162.	1.7	6
101	Sudden Infant Death Syndrome, Childhood Thrombosis, and Presence of Genetic Risk Factors for Thrombosis. <i>Thrombosis Research</i> , 2000, 98, 233-239.	1.7	6
102	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019, 48, 236-243.	1.7	6
103	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 791-800.	1.5	6
104	Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0152269.	2.5	6
105	Oral anticoagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. <i>British Journal of Haematology</i> , 2022, 197, 223-231.	2.5	6
106	Assigning diagnosis codes using medication history. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102307.	6.5	6
107	Female sex is associated with a lower risk of stroke in patients with heart failure. <i>American Heart Journal</i> , 2015, 169, 396-403.e2.	2.7	5
108	Using a personalized decision support algorithm for dosing in warfarin treatment: A randomised controlled trial. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2017, 25, 1-6.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, 463-472.e5.	1.5	5
110	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 31-39.	3.0	5
111	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2022, 53, 2559-2568.	2.0	5
112	Monitoring of anticoagulant therapy applying a dynamic statistical model. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 110, 380-388.	4.7	4
113	Misconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, e31.	1.5	4
114	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	4
115	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. <i>American Journal of Medicine</i> , 2021, , .	1.5	4
116	Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3847-3855.	2.4	4
117	Denaturing High-performance Liquid Chromatography mutation analysis in patients with reduced Protein S levels. <i>Clinica Chimica Acta</i> , 2008, 390, 76-81.	1.1	3
118	More Studies on Outcomes Using Biochemical Diagnostic Tests Are Needed: Findings from the Danish Society of Clinical Biochemistry. <i>Clinical Chemistry</i> , 2008, 54, 1254-1256.	3.2	3
119	The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thrombosis Research</i> , 2009, 124, 208-212.	1.7	3
120	Letter by Christensen et al Regarding Article, "New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation": <i>Circulation</i> , 2012, 126, e45; author reply e46.	1.6	3
121	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 447-455.	1.5	3
122	Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 30-38.	2.5	3
123	Extended oral anticoagulation after incident venous thromboembolism "a paradigm shift?". <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 201-208.	1.5	3
124	Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-11.	2.5	3
125	Haemostatis activity in rectal cancer patients exposed to preoperative radiotherapy: a clinical prospective cohort study. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 276-282.	1.0	2
126	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 61, 596.	2.8	2

#	ARTICLE	IF	CITATIONS
127	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e026159.	1.9	2
128	Management of Cancer-Associated Venous Thrombosis: A Nationwide Survey among Danish Oncologists. <i>TH Open</i> , 2021, 05, e188-e194.	1.4	2
129	Characteristics of patients receiving extended treatment after incident venous thromboembolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 332-342.	2.5	2
130	Towards Assigning Diagnosis Codes Using Medication History. <i>Lecture Notes in Computer Science</i> , 2020, , 203-213.	1.3	2
131	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1155-1163.	1.5	1
132	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 785-790.	1.7	1
133	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1672-1682.	3.2	1
134	Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting. <i>PharmacoEconomics - Open</i> , 2022, 6, 483-494.	1.8	1
135	D-dimer test in deep vein thrombosis - reply. <i>Journal of Internal Medicine</i> , 2002, 252, 576-576.	6.0	0
136	Severe arterial thrombosis in a family with type III protein S deficiency caused by a frameshift mutation in the <i>PROS1</i> gene. <i>Thrombosis Research</i> , 2010, 126, e159-e161.	1.7	0
137	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e21.	1.5	0
138	Management of paediatric arrhythmias in Europe: authors' reply. <i>Europace</i> , 2015, 17, 1879.2-1880.	1.7	0
139	Comparison of Atrial Fibrillation Guidelines. <i>Journal of General Internal Medicine</i> , 2015, 30, 1404-1404.	2.6	0
140	EHRA research network surveys: 6 years of EP wires activity. <i>Europace</i> , 2015, 17, 1733-1738.	1.7	0
141	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients. <i>Europace</i> , 2015, 17, 169-170.	1.7	0
142	Stroke and mortality after atrial fibrillation—a global struggle. <i>Lancet, The</i> , 2016, 388, 1131-1132.	18.7	0
143	Letter by Nielsen et al Regarding Article, “Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1: Systematic Review and Meta-Analysis” <i>Stroke</i> , 2016, 47, e193.	2.0	0
144	Response. <i>Chest</i> , 2016, 149, 1590-1591.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Risk of venous thromboembolism in patients with heart failure. <i>Lancet Haematology</i> , 2016, 3, e6-e7.	4.6	0
146	All Types of Hemorrhagic Stroke Are Not Created Equally—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 1399.	5.1	0
147	Response by Overvad et al to Letter Regarding Article, “Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ -DS ₂ -VASc Score Rather Than CHA ₂ -DS ₂ -VASc?” <i>Circulation</i> , 2018, 138, 443-444.	1.6	0
148	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021, 134, 67-75.e5.	1.5	0
149	Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 0, , .	3.4	0